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1. Introduction
Synthetic interfering RNAs (siRNAs) are 
double-stranded RNA duplexes able to 
suppress expression of a gene through a 
sequence-selective and enzymatic-medi-
ated mRNA degradation mechanism 
occurring in the cytosol of all mamma-
lian cells.[1] This gene silencing method 
is mediated by binding of siRNAs to the 
RNA-induced silencing complex (RISC)[2] 
and can be employed therapeutically in 
diseases with an identified genetic target. 
The pharmacological efficacy of siRNA is 
quite poor for two reasons. First, siRNA 
does not freely diffuse across the plasma 
membrane to reach its molecular targets. 
Second, siRNA is a biodegradable mole-
cule and it is rapidly eliminated by glo-
merular filtration. Various actions have 
been undertaken to enhance the phar-
macological profile of siRNA. Optimiza-
tion of the chemical structure of siRNA enhances resistance 
to nuclease and conjugation to ligands enables hepatocyte tar-
geting.[3] Aside, the siRNA can be assembled with a carrier into 
a delivery system. Encapsulating the siRNA with a carrier into 
a particle improves siRNA stability[4] and shielding the parti-
cle’s surface with polyethyleneglycol[5] and/or tissue-targeting 
ligands is an effective mean to improve biodistribution.[6] Modi-
fying the chemical structure of the carrier can improve the 
siRNA transfer into the cytosol across the plasma membrane 
and molecules such as cationic lipids,[7] polymers,[8] or lipid-
like molecules[9] have been made for that purpose. However, 
properties increasing siRNA resilience in the blood do not typi-
cally allow for cytosolic release. Conception of in vivo delivery 
system is thus challenging. Several delivery systems have none-
theless demonstrated the potential of the siRNA-mediated gene 
silencing technology in animal models of disease.[10] Optimized 
siRNA formulations were even tested in a phase I clinical trial 
for treatment of patients with advanced cancers.[11] The formu-
lations were generally well-tolerated and provided therapeutic 
benefits to some patients. However, further improvements are 
needed.[12]
To improve the siRNA translocation across the plasma 
membrane, we have used modified polyethylenimine (PEI). 
Medical application of siRNAs relies on methods for delivering nucleic acids 
into the cytosol. Synthetic carriers, which assemble with nucleic acids into 
delivery systems, show promises for cancer therapy but efficiency remains to 
be improved. In here, the effectiveness of pyridylthiourea-polyethylenimine 
(πPEI), a siRNA carrier that favors both polyplex disassembly and endosome 
rupture upon sensing the acidic endosomal environment, in 3 experimental 
models of hepatocellular cancer is tested. The πPEI-assisted delivery of a 
siRNA targeting the polo-like kinase 1 into Huh-7 monolayer produces a 90% 
cell death via a demonstrated RNA interference mechanism. Incubation of 
polyplex with Huh-7 spheroids leads to siRNA delivery into the superficial 
first cell layer and a 60% reduction in spheroid growth compared to untreated 
controls. Administration of polyplexes into mice bearing subcutaneous 
implanted Huh-7Luc tumors results in a reduced tumor progression, similar 
to the one observed in the spheroid model. Altogether, these results support 
the in vivo use of synthetic and dedicated polymers for increasing siRNA-
mediated gene knockdown, and their clinical promise in cancer therapeutics.
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PEI is a nucleic acid delivery polymer known for its ability 
to become protonated in the endosome and for its endoso-
molytic activity.[13] The PEI has also been tested in clinical 
trials.[14] We noticed that electrostatic association between the 
siRNA and the water-soluble PEI was insufficient for main-
taining the siRNA/PEI assembly cohesiveness in serum-con-
taining cell culture medium. Subsequent polyplex anchorage 
to cell membrane and internalization in endosome in enough 
quantities is hence compromised. We therefore enhanced 
the polyplex stability using complementary hydrophobic 
polymer–polymer interactions by rendering the 25 kDa PEI 
insoluble at pH > 7.0.[15] The PEI hydrophobicity was carefully 
adjusted for triggering solubilization through protonation of 
the hydrophobic PEI only inside the endosomes. A pH-con-
trolled intracellular siRNA release is hence obtained. Among 
several hydrophobic PEIs, we selected pyridylthiourea-grafted 
polyethylenimine (πPEI) as our leading pH-responsive carrier. 
This modification improves considerably siRNA delivery effi-
ciency in monolayer cell cultures.[16] In addition, πPEI assem-
bles siRNA into polyplexes with mean diameters slightly below 
100 nm, regardless of the πPEI ethylenimine (N) to siRNA 
phosphate (P) N/P ratio[16] and showed promises for in vivo 
siRNA delivery.[17] However, The πPEI has not been tested for a 
siRNA-mediated tumor therapeutic experiment.
Hepatocellular cancer (HCC) represents a major health 
concern. In 2012, the World Health Organization estimated 
HCC 745 000 deaths worldwide, encompassing ≈9.1% of all 
cancer deaths.[18] Recent reports in the United States also 
establish hepatic cancer as a major burden. From 2003 to 
2012 liver cancer-associated death rates increased, compared 
to a reduced overall cancers morbidity.[19] HCC is frequently 
associated with cirrhosis, which can make the liver extremely 
sensitive to hazardous substances. SiRNA delivery systems 
preferentially accumulate in the liver (either in hepatocytes 
or Kupffer’s cells) upon intravenous administration.[20] This 
tropism might raise concerns of adverse liver damage even if 
the tropism for liver may be reduced by equipping the nano-
particles with a tumor-targeting element.[6b] An alternative is 
to administer the nanoparticles into the tumor by performing 
weakly invasive surgical procedures.[21] Before engaging in 
such surgical procedure, our objective was to provide evi-
dence of an antitumoral activity of siRNA/πPEI polyplexes 
in hepatocellular carcinoma models using a local administra-
tion procedure. The polo-like kinase 1 was chosen because 
this protein is essential during cell division and is a feasible 
target for cancer therapy.[10c,22] The siRNA/πPEI polyplexes 
were evaluated in two in vitro HCC models and in one in vivo 
model to identify translational performance. The first model 
was the classical in vitro 2D culture of Huh-7 cells onto plastic 
substrates. The second model was Huh-7 spheroid culture, in 
which in their 3D growth displays aspects like endogenous 
tumor morphology.[23] The third model consisted of subcuta-
neously implanted Huh-7 tumor mouse.[24] Our results con-
firmed the siRNA delivery efficiency of πPEI-based systems 
both in vitro and for in vivo following topical administration. 
Moreover, the Huh-7 spheroid cultures appeared more predic-
tive of in vivo performance at least in terms of efficiency. The 
spheroid in vitro model may be helpful to choose more effec-
tive carriers.
2. Results and Discussion
2.1. Description of the Experimental Setting
The antitumoral activity of siRNA in HCC has been evaluated 
using various genetic targets and delivery systems. Kawata et al. 
demonstrated that a polyplex of atelocollagen with siRNA tar-
geting the polo-like kinase 1 (siPLK) reduced mouse liver meta-
static proliferation.[25] Judge et al. describes the antitumoral 
efficacy of stable nucleic acid particles containing a chemi-
cally modified siPLK for treatment of mouse hepatic tumor 
models.[10c] Li et al. evaluated several lipidic formulations and 
genetic targets and suggested that one novel lipid formula-
tion and a siRNA targeting CDCA1 are efficient for HCC 
treatment.[26] Tabernero et al. reported an encouraging out-
come from a phase I clinical trial describing both safety and 
efficacy of ALN-VSP, a stable lipid formulation containing two 
siRNAs that target the vascular endothelial growth factor and 
the kinesin spindle protein.[11] We decided to target the polo-
like kinase 1 for the following four reasons. First, the polo-like 
kinase 1 (PLK-1) plays critical role during mitotic progres-
sion.[27] Its inhibition blocks cell cycle in mitosis and may 
induce apoptosis.[28] Second, PLK-1 elevations are observed in 
many tumor-types, where it is predictive of a poor prognosis.[29] 
Third, several investigations at preclinical stage[30] including 
two on HCC models,[10c,24a] confirmed the antitumoral poten-
tial of targeting PLK1 using the siRNA technology. Fourth, 
optimized siRNA sequences (including the control) and 2′OMe 
nucleotides chemical modification that minimize immune 
response were described (Figure 1A).[10c] At the cellular level, 
siRNA-mediated polo-like kinase 1 inhibition blocks the cell 
mitosis as early as the prophase (Figure 1B) and causes a typical 
nuclear morphology that is easy to observe using microscope. 
The human hepatoma cell line Huh-7 can be grown in either 
2D and 3D cultures, and implanted into immunodeficient mice 
(Figure 1C). Implanted Huh-7 tumors can also constitutively 
express a firefly luciferase for a longitudinal detection of tumor 
growth using a luminescence in vivo imaging system.[24b] 
Regarding the delivery system, the siRNA/πPEI polyplexes 
were always assembled in 4.5% glucose, pH 6.3 using concen-
trated 0.2 m πPEI. This condition produces an homogenous col-
loidal suspension of spherical particles with mean diameters 
slightly below 100 nm, regardless of the πPEI ethylenimine (N) 
to siRNA phosphate (P) N/P ratio.[16]
2.2. Gene Silencing into 2D Culture Model
We initially tested the ability of the siPLK and πPEI to selec-
tively silence the polo-like kinase 1 in the Huh-7 hepatoma 
cells cultivated in the 2D classical setting. Under this experi-
mental condition, adherent cells have a large portion of the 
outer plasma membrane surface exposed toward the medium, 
allowing direct and unrestricted cellular anchorage of particles. 
The polyplexes containing either the control siRNA (siC) or the 
siPLK were assembled in 4.5% glucose at a N/P ratio of 125. 
The polyplexes were then directly added to the cells by dilution 
with the serum-containing cell culture medium. Total mRNA 
was then extracted at various time points after polyplex addition. 
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PLK-1 mRNA levels were quantified by real-
time polymerase chain reaction (PCR). Nor-
malization of the PLK-1 mRNA levels was 
performed versus the GAPDH, PSMB2, and 
SNRPD3 housekeeping genes.[31]
The PLK-1 mRNA expression was 
reported as a percentage versus untreated 
cells (Figure 2A). In the untreated and 
siC/πPEI-treated samples, the PLK1 mRNA 
levels remained roughly constant at all time 
points. In the siPLK/πPEI-treated sam-
ples, the level of intact PLK1 mRNA rapidly 
decreased. A 50% diminution was already 
obtained 3 h after polyplex addition and the 
maximum 90% diminution was reached in 
12 h. During RNA interference the siPLK 
typically acts in the RNA-induced silencing 
complex (RISC) to promote a sequence-
selective cleavage of mRNA targets between 
the nucleotides 9 and 10 from the siRNA 
sense sequence (arrow, Figure 1A). To 
Global Challenges 2017, 1700013
Figure 1. Illustration of described experiments. A) Sequence of the polo-like kinase 1 (PLK-1) and control siRNAs. The underlined nucleotides are 
2′OMe. The arrow indicates the cleavage site on the targeted PLK-1 mRNA. B) Representation of the mitotic cell cycle. Inhibition of the PLK-1 with 
siRNA blocks the cells entering mitosis in prophase. C) Illustration of the different hepatocellular cancer (HCC) models that were used.
Figure 2. Demonstration of the efficiency of siRNA-mediated gene silencing activity using 
siRNA/πPEI polyplexes. A) Quantification of intact PLK1 mRNA level in untreated Huh-7 cells 
(UC, white triangles), siC/πPEI (blue hatched squares) or siPLK/πPEI (black dots)-treated cells. 
The siC and siPLK correspond to untargeted and polo-like kinase 1-targeting siRNAs. Final 
concentrations were at 20 × 10−9 m siRNA and 100 × 10−6 m πPEI. Complexes were added directly 
to Huh-7 cell monolayer in serum containing cell culture medium. B) 5′RACE-PCR analysis of 
polyplexes-treated cells to detect of the siPLK/RISC-promoted mRNA fragmentation. The arrow 
points to the expected length of the siPLK-specific RACE-PCR product.
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confirm this mechanism of RNA interference, we isolated the 
5′phosphate-RNA fragment using the 5′-RACE-PCR assay.[10c] 
Here, the size of the 5′-RACE-PCR product corresponding 
to the siPLK-cleaved mRNA fragment was predicted to be 
441 bp. The gel electrophoresis analysis showed that only the 
siPLK/πPEI-treated Huh-7 cells produced DNA fragments 
amplification (Figure 2B). The size of the major fragment cor-
responded to its predicted size, providing further evidence that 
the diminished PLK1 mRNA level was caused by a RNA interfer-
ence mechanism. Next, the therapeutic activity of siPLK in 2D 
culture was assayed by staining the cellular DNA with Hoechst 
33342 2 d after addition of siRNA/πPEI polyplexes (siRNA 
being either siC or siPLK) (Figure 3A). The cell nuclei in the 
siC/πPEI-treated experiments looked similar in both shape and 
proportion of mitotic cells to untreated Huh-7 cells (Figure 3A1). 
πPEI-delivered siPLK induced dramatic nuclear modifications 
in over 90% of cells. Genomic DNA appeared fragmented, indi-
cating an irreversible block in mitotic progression as early as 
prophase, leading to apoptosis as indicated by substantial 
DNA fragmentation during longer incubation times (see 
Figure S1 in the Supporting Information). We performed next 
a dose–response experiment variation of πPEI concentration 
and maintained the concentration of siRNA at 20 × 10−9 m 
(Figure 3B). The percentage of mitosis-arrested cells increased 
with increasing πPEI concentration and reached a maximum of 
an over 90% mitotic blockage at 100 × 10−6 m πPEI.
Overall, these experiments confirmed that πPEI is able to 
deliver siPLK into Huh-7 cells with excellent efficiency and 
leads to a mitotic blockage via a siPLK1/RISC-induced mRNA 
fragmentation.
2.3. Gene Silencing in 3D Cultured Cells (Spheroids)
Since the siPLK/πPEI polyplex can efficiently block Huh-7 pro-
liferation, we next evaluated the performance and behavior of 
Global Challenges 2017, 1700013
Figure 3. Cellular response to siRNA-mediated PLK1 mRNA degradation 2 d after addition of siRNA/πPEI onto Huh-7 2D cultures. A) The morphology of the 
cell nuclei was observed after staining with Hoechst 33342. Final concentrations were at 20 × 10−9 m siRNA and 100 × 10−6 m πPEI. B) Analysis of prophase-
blocked Huh-7 as a function of πPEI concentration. The siRNA concentrations were fixed at 20 × 10−9 m and the polyplexes were added 48 h before analysis.
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the polyplexes for siRNA delivery in 3D tissue culture. Tumor 
spheroids consist of multiple cells grown into a sphere and are 
in vitro model for tumorogenesis especially at early states.[32] 
Huh-7 spheroids were grown using a hanging drop method[33] 
until diameters reach ≈120–150 μm. These spheroids were then 
incubated with siRNA/πPEI polyplexes and their growth over 
9 d was determined by measuring spheroid volume from cali-
brated images (Figure 4). Between the days 2 and 9, untreated 
spheroid volume increased roughly 20 folds. The volumes of 
siC/πPEI- and siPLK/πPEI-treated spheroids showed 20% and 
60% growth reductions, respectively.
The localization of the siRNA polyplexes within the sphe-
roids was assayed by incubating Huh-7 spheroids with a πPEI 
polyplex containing a Rhodamine-labeled siRNA during 24 h. 
After membrane staining with pKH67, confocal imaging was 
performed (Figure 5A,B). Fluorescently labeled siRNA/πPEI 
polyplexes remained bound to the spheroid surface, but do 
not penetrate inside the sphere core. Incubation of the sphe-
roid with siPLK1/πPEI polyplexes produced a similar result 
(Figure 5C). Nuclear fragmentation typical of polo-like kinase 
1 gene silencing was observed only in the superficial cell layers. 
These results are in accordance with previous works showing 
that polyplex[34] and, more generally particles sized over 5 nm, 
do not easily reach the interior of the tumor.[35] Altogether, these 
data demonstrate that the polyplexes can only bind and deliver 
siRNA to the first outer cell layer of the spheroid. Reduced 
internal accessibility maybe why siPLK polyplexes reduce sphe-
roid proliferation but do not induce full regression.
2.4. In Vivo Evaluation of πPEI-Delivered siRNA
Nanoparticular delivery systems can elicit 
production of proinflammatory cytokines 
(TNF-α, IFN-γ, and IL-12) and a cascade 
of immune response events causing tox-
icity but also, in some cases, tumor growth 
reductions.[36] We evaluated the potential of 
siRNA/πPEI polyplexes to trigger an inflam-
matory response in healthy immunocom-
petent Balb/c mice by measuring release 
of several proinflammatory cytokines. The 
2′-OMe-modified SiC was reported not to 
trigger release of proinflammatory cytokines 
in animal.[10c] It was hence associated with 
πPEI. The polyplex (N/P 14, 20 μg siRNA; 
70 μg πPEI/mouse) was intravenously 
injected into the tail vein of Balb/c mice and 
blood samples were collected at different time 
points for quantification of plasma cytokine 
concentrations (Figure 6). Administration of 
the siC alone, or in complex, did not trigger 
release of TNF-α, IFN-γ, IL-1β, and IL-12 
within a 24 h period. A transient plasma 
release of IL-6 was observed at 6 h when the 
siRNA was provided alone or in complex 
with πPEI. This induction (160 pg mL−1) 
was moderate compared to lipopolysaccha-
ride (>24 000 pg mL−1) or siRNA/PEI poly-
plexes (>1200 pg mL−1) response.[37] The fate 
of intravenously injected Cy5-siRNA/πPEI 
polyplexes was longitudinally monitored 
using a fluorescence in vivo imaging system 
(Figure S2, Supporting Information). Poly-
plexes accumulated in the liver as expected for 
nanoparticular systems.[38] Hepatic damage 
was evaluated by measuring the plasma levels 
of alanine aminotransferase (ALAT), aspar-
tate aminotransferase (ASAT), and cytosolic 
lactate dehydrogenase (LDH) 24 after injec-
tion (Figure 6A). Plasma ALAT and ASAT 
levels were low, indicating siC/πPEI does not 
promote acute liver damage at tested dosages. 
Global Challenges 2017, 1700013
Figure 4. In vitro growth of Huh-7 3D tumors in presence of siRNA polyplexes. A) Representa-
tive images of spheroid’s growth over time in absence or presence of siC/πPEI and siPLK/πPEI. 
B) Plot showing the average (± SD, n = 7) volumetric growth over time of untreated sphe-
roids (white triangles) or ones that were incubated with siC/πPEI (blue hatched squares) or 
siPLK/πPEI (black dots). The spheroid volume (%) was reported relative to the first day.
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A LDH activity (500 U L−1) was detected in the plasma but was 
comparable to the response triggered by injection of PEI.
We next evaluated siPLK/πPEI polyplexes performance in 
a hepatic cancer model where immunodeficient nude mice 
were engrafted with luciferase-expressing Huh-7 tumors.[24b] In 
an initial experiment, luciferase-expressing Huh-7 xenografts 
were established orthotopically near the liver of immunodefi-
cient mice. The siRNA/πPEI polyplexes (N/P 14) containing a 
Cy5-siRNA were then intravenously injected. Differential accu-
mulation of the polyplex into the tumor and in the liver was 
measured 24 h after injection (Figure S3, Supporting Infor-
mation). The polyplex was detected in both the liver and the 
nearby tumor. Polyplex tumor accumulation was moderate and 
heterogeneous, confirming that the iv administration of cati-
onic siRNA/πPEI polyplex is not effective. We then evaluated 
the performance of siRNA/πPEI polyplex injected directly into 
the tumor of subcutaneous luciferase-expressing Huh-7 xeno-
graft mouse tumors. Three weeks after implantation, the tumor 
bioluminescence was measured in 3 experimental groups: 
siPLK/πPEI, siC/πPEI, and vehicle (4.5% glucose solution). 
Global Challenges 2017, 1700013
Figure 5. Visualization of siRNA/πPEI delivery within the spheroid. A,B) Rhodamine-siRNA/πPEI polyplexes (N/P 14) were incubated 24 h with a sphe-
roid in the cell culture medium containing serum at final concentrations of 180 × 10−9 m siRNA and 100 × 10−6 m πPEI. The spheroid was then fixed 
with paraformaldehyde and the cell membranes were stained with PKH67 fluorescent cell linker kit. The spheroid was observed at three focal plans 
for visualization of the cell membrane (A, green fluorescence) or for visualization of the Cy5-siRNAs polyplexes (B, red fluorescence). C) The Huh-7 
spheroid was incubated with siPLK/πPEI for 9 d. The spheroids were fixed and the nuclei stained with Hoechst 33342.
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All groups followed a treatment protocol consisting of 6 intra-
tumoral administrations at days 0, 2, 4, 7, 9, and 11 of either 
the vehicle alone (4.5% glucose solution, 50 μL), siC/πPEI 
or siPLK/πPEI polyplexes (20 μg siRNA, 50 μg πPEI, 50 μL). 
During this time, the tumor growth was evaluated by measuring 
the bioluminescence of Huh-7-Luc tumors in anesthetized 
mice (Figure 7A). This treatment regime did not induce weight 
loss, nor adverse behavioral modifications. Both at the begin-
ning and end of treatments protocol siPLK/πPEI-treated mice 
showed a low luminescence signals emitted by the siPLK/πPEI-
treated tumors. After normalization of the bioluminescence 
level, the relative tumor growth (RTG) of each group was 
plotted over the treatment time course (Figure 7B). SiPLK/πPEI 
significantly diminished the tumor growth from 7 d onward 
versus control groups (p < 0.05, Mann–Whitney rank sum test). 
Using the same administration protocol, controls were per-
formed using siRNA/PEI polyplexes containing unmodified 
PEI or sticky siRNA[39] (Figure S4, Supporting Information). 
With these complexes, diminished tumor growths were also 
obtained, but were not specific to the polo-like kinase 1 siRNA. 
At the end of the treatment protocol (day 14), the mice were 
euthanized. The tumors were excised and were subjected to 
histological analyses (Figure 7C).
Necrosis was blindly scored and higher levels were observed 
in the PLK1/πPEI-treated tumors compared with controls. The 
PLK1mRNA levels within treated tumors were finally quanti-
fied using RT-PCR after a single injection of the polyplexes 
containing siC or siPLK (Figure S5, Supporting Information). 
A 40% reduced PLK1 mRNA level was observed only in the 
siPLK/πPEI-treated group, suggesting that the antitumoral 
activity is mostly promoted by siPLK1 delivery with πPEI.
3. Conclusion
The usefulness of polyethylenimine as a carrier for nucleic 
acids has been evaluated in phase I/II clinical trials in 
patients with invasive bladder tumors[14a] or advanced pan-
creatic cancer.[14b] In both trials, nucleic acid/PEI polyplexes 
were administrated locally. No serious adverse effects were 
observed indicating that local administration coupled to a sur-
gical procedure may provide benefits. We showed here that 
Figure 6. In vivo evaluation of the immune response to injected polyplexes. Immunocompetent Balb/c mice were intravenously injected with 1 mg kg−1 
siC (hatched blue square) or siC/πPEI (black dots). A–E) Blood samples were collected at various times postinjection and plasma concentrations 
(in pg mL−1) were determined for TNF-α, interferon γ, IL-1β, IL-12, and IL-6. F) The presence of hepatic enzymes in the plasma was measured 24 h 
after injection. Data are expressed as mean ± SD (n = 8). The basal plasma levels (white bar) of each component were measured in blood samples 
collected 48 h before injection. For convenience, this value was plotted at 0 h.
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pyridylthiourea-polyethylenimine assists the antimitotic activity 
of a siRNA targeting the polo-like kinase 1 into the Huh-7 cell 
line via an RNA interference mechanism. πPEI delivery effi-
ciency was maximal when the polyplexes were incubated onto 
cell grown in vitro as monolayer. Here over 90% RNAi-mediated 
cell-arrest and cell death was obtained. When the polyplexes 
were incubated with Huh-7 grown as spheroid, delivery perfor-
mance was reduced by about 60% likely as only the superficial 
cells of the spheroid were accessible. Intratumoral administra-
tion of the polyplexes into implanted hepatic tumors slowed 
tumor growth, an antitumoral effect linked to diminished 
intracellular polo-like kinase 1 mRNA levels. Administration 
of polyplex into fully immunocompetent Balb/c mice triggered 
a minimal release of proinflammatory cytokines. Altogether, 
these results support the medical application of nucleic acid 
delivery systems based on polyethylenimine when topical 
administration is feasible. We believe that the progress in sur-
gery procedures renders topical applications more and more 
feasible and should open opportunities for blood-incompatible 
but efficient in vitro siRNA delivery systems. Our results also 
clearly indicate that polyplex does not reach buried cell surface 
on their own but likely relies on cellular mobility or a tumor 
invasion of the injected sites for efficacy.
4. Experimental Section
Detailed experimental procedures are reported in the Supporting 
Information. Animal experimentations were performed in accordance 
with European recommendations (Directive 2010/63/UE, September 22, 
2010) and French regulations (Décret 2013-118, February 1, 2013). They 
received the approval no. 00465.02 from the French Ministry of Higher 
Education and Research in date of March 11, 2014.
Supporting Information
Supporting Information is available from the Wiley Online Library or 
from the author.
Figure 7. Evaluation of antitumoral activity of siPLK/πPEI in a mice model of hepatocellular cancer. A) In vivo bioluminescence imaging of representa-
tive mice implanted with subcutaneous Huh-7-Luc tumors. The bioluminescence activity, expressed as p s−1 cm−2 sr−1, is indicated under each image. 
B) Quantification of relative tumor growth. The vehicle alone (glucose solution), siC/πPEI, and siPLK/πPEI (20 μg siRNA; 70 μg πPEI) were repeatedly 
injected into tumors over two weeks at times indicated by the arrows. The relative tumor growth (RTG) was calculated as the ratio of luciferase activity at 
d14 to the luciferase activity at d0. Bioluminescence imaging acquisitions were performed before products’ injections. The mean ± SE luciferase activity 
at day 0 for the vehicle, siC/πPEI, and siPLK/πPEI groups was, respectively, 3.8 × 106, 4.6 × 106, and 6.5 × 106 p−1 s−1 cm−2 sr−1 and RTG is expressed as 
mean ± SE of ratios between luciferase activity at the indicated day to the luciferase activity at d0 (n = 12/group). The diamond () indicates significant 
variation between groups (p < 0.05) using a Mann–Whitney test. C) Hematoxylin/eosin staining of tumors at day 14 after the indicated treatment.
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